| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 115.1MM | +11% |
| Gross Profit | 103.8MM | +11% |
| Cost Of Revenue | 11.3MM | +14% |
| Operating Income | -3.7MM | -78% |
| Operating Expenses | 107.5MM | -3% |
| Net Income | -33.8MM | +57% |
| R&D | 35MM | -14% |
| G&A | 70.2MM | +7% |
| Interest Expense | 12.8MM | -1% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Amicus Therapeutics, Inc. ( NASDAQ:FOLD ) is possibly approaching a major achievement in its business, so we would like...
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today issued its fourth annual Environmental, Social, and Governance (ESG) report. This year’s report highlights the strength of the Company’s corporate responsibility structure including increased efforts towards transparency in our environmental reporting, our deep commitment to ensu
In this article, we’re going to take a look at 13 best biotech stocks to buy under $20. To see more stocks that made the list, you can skip ahead and jump straight to the top 5 best biotech stocks to buy under $20. When it comes to investing, few industries are as exciting to […]
Director Margaret Mcglynn has sold 15,000 shares of Amicus Therapeutics Inc (NASDAQ:FOLD) on March 5, 2024, according to a recent SEC Filing.
Amicus Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating
Last week saw the newest full-year earnings release from Amicus Therapeutics, Inc. ( NASDAQ:FOLD ), an important...
Amicus Therapeutics ( NASDAQ:FOLD ) Full Year 2023 Results Key Financial Results Revenue: US$399.4m (up 21% from FY...
PRINCETON, N.J., March 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in March. Cowen 44th Annual Health Care Conference in Boston, MA, on Monday, March 4, 2024, at 11:10 a.m. E.T.Leerink Partners 2024 Global Biopharma Conference in Miami, FL on Monday, March 11, 2024, at 3:20 p.m. E.T. A live audio webcast of each presentation can also be accessed via the investors s
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2023 Earnings Call Transcript February 28, 2024 Amicus Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning ladies and gentlemen and welcome to the Amicus Therapeutics’ Full Year 2023 Financial Results Conference […]